Table 2.
The post-transformation gene mutations of NGS in the 10 patients.
| Gene (Mutation point) |
Patients (Mutation abundance (%)) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | |
| EGFR | Exon 19 del | Exon 19 del | Exon 21 L858R | ✘ | Exon 19 del | Exon 21 L858R | Exon 19 del | Exon 21 L858R | Exon 19 del | Exon 21 L858R |
| T790M | ✘ | ✘ | ✘ | ✘ | ✓(12.4%) | ✘ | ✘ | ✘ | ✘ | ✓(17.6%) |
| RB1 loss | ✓(9.2%) | ✘ | ✓(6.5%) | ✓(13.4%) | ✓(15.2%) | ✘ | ✓(5.7%) | ✓(7.4%) | ✘ | ✓(13.7%) |
| TP53 | ✓ (p.A159D) (8.4%) | ✓(p.R273H)(13.7%) | ✓(p.R273H) (20.3%) | ✓(p.A159D) (17.8%) | ✓(p.A159D) (5.9%) | ✘ | ✓(p.A159D) (7.6%) | ✓(p.R273H) (13.4%) | ✓(p.R273H) (22.8%) | ✓(p.A159D) (14.6%) |
| MYC amplification | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✓(28.4%) | ✘ |
| NF1 (p.R461T) | ✘ | ✘ | ✘ | ✘ | ✘ | ✓(22.5%) | ✘ | ✘ | ✘ | ✘ |
| PIK3CA (p.E545K) | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✓(4.6%) | ✘ | ✘ | ✘ |
| PTEN loss | ✓(16.8%) | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| CCNE1 (Exon7, c.476A > G) | ✘ | ✘ | ✘ | ✓(8.9%) | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| CDK6 amplification | ✘ | ✓(14.2%) | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| BRAF (p.D594G) | ✘ | ✘ | ✓ (5.6%) | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
✓ indicating the presence of gene mutation, ✘ indicating the absence of gene mutation.